DEXI (dexamethasone-induced protein) is a regulatory protein that modulates immune responses and inflammatory signaling pathways. DEXI functions as a positive regulator of type I interferon signaling in pancreatic beta cells, where it enhances IFNβ transcription and subsequent STAT1 activation in response to viral double-stranded RNA stimuli 1. The protein appears to bind chr16 and directly regulate IFNβ promoter activity, with DEXI silencing reducing proinflammatory chemokine production and DEXI overexpression increasing STAT1 and inflammatory mediator levels 1. DEXI has been implicated as a candidate gene for multiple autoimmune diseases, with protective genetic variants in the neighboring CLEC16A gene associated with increased DEXI expression through long-range chr16 looping interactions 2. The gene has been linked to type 1 diabetes, multiple sclerosis, and Alzheimer's disease susceptibility through genome-wide association studies 234. However, functional studies in NOD mice demonstrated that Dexi deficiency does not affect diabetes development, suggesting CLEC16A rather than DEXI may be the causal gene at the 16p13 locus 5. In cancer contexts, DEXI appears to promote tumor progression, as miR-3960-mediated DEXI suppression inhibits bladder cancer growth 6.